

PB60786USW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bravi et al.  
Serial No.: To Be Assigned Group Art Unit:  
File Date: Concurrently Herewith Examiner:  
For: 4-Carbox Pyrazole Derivatives Useful As Anti-Viral Agents

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: Ref. 5-11  
☐ Copies of the references were submitted in parent application \_\_\_\_\_ (37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/GB2006/001071 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a

counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(l)(1) (\$130.00) is submitted herewith.

- ☒ Please charge any required fees to Deposit Account No. 07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Karen L. Prus  
Registration No. 39,337

Date: *September 26, 2006*  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-2192  
Facsimile: (919) 483-7988

Sheet 1 of 3

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PB00786USW	SERIAL NO. To Be Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		APPLICANT Bravi et al.	
		FILING DATE Concurrently Herewith	GROUP

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation Yes No	
1	WO-03037893	05-08-2003	WO				
2	WO-03037895	05-08-2003	WO				
3	WO-2004078415	09-10-2004	WO				
4	WO-2004096210	11-11-2004	WO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)**


Examiner Signature	Date Considered
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PB60766USW	SERIAL NO. To Be Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		APPLICANT Bryvi et al.	
		FILING DATE Concurrently Herewith	GROUP

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No
5	WO-0069562	11-09-2000	WO			
6	WO-0102885	01-11-2001	WO			X
7	WO-04052885	06-24-2004	WO			
8	WO-9600218	01-04-1996	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

9	MASSA S ET AL.; Heterocyclic System. XI. Synthesis of 1H,4H-Pyrazolo[4,3-b]pyrrolizine and 2H,4H-Pyrazolo[4,3-b]pyrrolizine Derivatives; J. Heterocyclic Chem.; 1990; 27(6); 1805-1808;
10	SENDA S ET AL.; Pyrimidine Derivatives and Related Compounds. XIII. The Synthesis of N-Substituted Pyrazolo[3,4-d]pyrimidines from Pyrazole Derivatives; Chem Pharm. Bull.; 1972; 20(2); 381-395;
11	VON HOLLEBEN M.L.A. ET AL.; A Selective Reduction of $\alpha,\beta$ -Unsaturated Ketones; Tetrahedron; 1994; 50(4); 973-978;

Examiner Signature	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	